BLUE - Bluebird Bio Inc Stock Price, Fair Value and News

1.21USD+0.01 (+0.83%)Market Closed

Market Summary

USD1.21+0.01

Market Closed

0.83%

BLUE Stock Price

View Fullscreen

BLUE RSI Chart

BLUE Valuation

Market Cap

112.6M

Price/Earnings (Trailing)

-1.19

Price/Sales (Trailing)

4.98

EV/EBITDA

0.66

Price/Free Cashflow

-0.39

BLUE Price/Sales (Trailing)

BLUE Profitability

Operating Margin

-9.98%

EBT Margin

-419.48%

Return on Equity

-40.97%

Return on Assets

-14.86%

Free Cashflow Yield

-259.24%

BLUE Fundamentals

BLUE Revenue

Revenue (TTM)

21.7M

BLUE Earnings

Earnings (TTM)

-91.2M

Breaking Down BLUE Revenue

Last 7 days

3.5%

Last 30 days

25.3%

Last 90 days

29.4%

Trailing 12 Months

-69.9%

How does BLUE drawdown profile look like?

BLUE Financial Health

Current Ratio

1.55

BLUE Investor Care

Shares Dilution (1Y)

31.87%

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	4.0M	9.4M	21.7M	0
2022	4.7M	6.1M	5.1M	3.6M
2021	189.0M	127.2M	65.4M	3.7M
2020	54.1M	239.7M	250.0M	250.7M
2019	51.1M	56.5M	53.9M	44.7M
2018	44.6M	35.7M	39.5M	54.6M
2017	11.5M	26.7M	32.8M	35.4M
2016	9.2M	5.8M	6.1M	6.2M
2015	25.4M	24.0M	19.0M	14.1M
2014	25.4M	25.4M	25.4M	25.4M
2013	1.4M	7.6M	13.9M	20.2M
2012	0	274.7K	307.3K	340.0K
2011	0	0	0	242.0K

Get all data in R, Python etc through our Historical Stock Data APIs

About Bluebird Bio Inc

bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ÃƒÆ’Ã…Â¸-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy. The company's clinical development programs include HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ÃƒÆ’Ã…Â¸-thalassemia. It has license agreement with Orchard Therapeutics Limited. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Somerville, Massachusetts.

CEO	Mr. Andrew Obenshain
WEBSITE	bluebirdbio.com
INDUSTRY	Biotechnology
EMPLOYEES	323

Bluebird Bio Inc Frequently Asked Questions

What is the ticker symbol for Bluebird Bio Inc? What does BLUE stand for in stocks?

BLUE is the stock ticker symbol of Bluebird Bio Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Bluebird Bio Inc (BLUE)?

As of Thu Jul 25 2024, market cap of Bluebird Bio Inc is 112.62 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of BLUE stock?

You can check BLUE's fair value in chart for subscribers.

Is Bluebird Bio Inc a good stock to buy?

The fair value guage provides a quick view whether BLUE is over valued or under valued. Whether Bluebird Bio Inc is cheap or expensive depends on the assumptions which impact Bluebird Bio Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for BLUE.

What is Bluebird Bio Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Jul 25 2024, BLUE's PE ratio (Price to Earnings) is -1.19 and Price to Sales (PS) ratio is 4.98. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. BLUE PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Bluebird Bio Inc's stock?

In the past 10 years, Bluebird Bio Inc has provided -0.282 (multiply by 100 for percentage) rate of return.